Abstract
Arterial hypertension is the main identifiable cardiovascular risk factor, and although the benefit of blood pressure reduction is universally acknowledged, the scientific community has long been divided over the therapeutic blood pressure targets to be reached, also considering the estimated overall cardiovascular risk and the presence of individual risk factors and associated comorbidities. During the last few years, numerous clinical studies and meta-analyses, in particular, the SPRINT study, have been published, demonstrating the advantages of an intensive antihypertensive treatment, over a target blood pressure value (<140/90 mmHg), in the reduction of major cardiovascular events, myocardial infarction, stroke, heart failure, and all-causes cardiovascular mortality. Stemming from these results the major International Guidelines revisited the therapeutic objectives, recommending blood pressure value <130/80 mmHg for the vast majority of hypertensive patients until the age of 65 and suggesting a reduction of the target also in the elderly. Numerous studies and meta-analyses demonstrated that the reduction of the risk of coronary or cerebral events, and of all-causes cardiovascular mortality, is independent from the baseline ...Continue Reading
References
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Aug 15, 2006·Journal of the American College of Cardiology·Ilke SipahiSteven E Nissen
Jul 12, 2007·The American Journal of Cardiology·William C CushmanUNKNOWN ACCORD Study Group
Sep 4, 2007·Lancet·Anushka PatelB Williams
Apr 2, 2008·The New England Journal of Medicine·Nigel S BeckettUNKNOWN HYVET Study Group
Jan 14, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·UNKNOWN JATOS Study Group
Jun 10, 2010·Hypertension·Toshio OgiharaUNKNOWN Valsartan in Elderly Isolated Systolic Hypertension Study Group
Apr 21, 2011·Journal of Hypertension·Gianpaolo ReboldiPaolo Verdecchia
Jun 5, 2013·The Journal of Clinical Hypertension·Yong WeiJiguang Wang
Jun 19, 2013·European Heart Journal·Giuseppe ManciaDavid A Wood
Sep 26, 2014·Journal of Hypertension·Costas ThomopoulosAlberto Zanchetti
Nov 11, 2015·Hypertension·Michelle C OddenPablo E Pergola
Nov 13, 2015·Lancet·Xinfang XieAnthony Rodgers
Jan 3, 2016·Lancet·Dena EttehadKazem Rahimi
May 20, 2016·JAMA : the Journal of the American Medical Association·Jeff D WilliamsonUNKNOWN SPRINT Research Group
Sep 4, 2016·Lancet·Emmanuelle Vidal-PetiotUNKNOWN CLARIFY Investigators
Feb 6, 2017·Journal of the American College of Cardiology·Chirag BavishiFranz H Messerli
Apr 30, 2017·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeGiuliano Tocci
May 12, 2017·Nature Reviews. Cardiology·Gema Ruiz-HurtadoLuis M Ruilope
Jun 22, 2017·Circulation·Gabriel S TajeuPaul Muntner
Nov 18, 2017·Journal of the American College of Cardiology·Paul K WheltonJackson T Wright
Dec 24, 2017·International Journal of Cardiology·Massimo VolpeGiuliano Tocci
Aug 31, 2018·European Heart Journal·Bryan WilliamsUNKNOWN ESC Scientific Document Group